Zantac / Ranitidine (NDMA Cancer) Attorney in Detroit, Michigan

Zantac Litigation in Detroit

Detroit's auto industry workforce represents a demographic with significant long-term OTC ranitidine use — industrial workers commonly used Zantac OTC for occupational stress-related GI issues through 2020. Michigan's 3-year SOL is more favorable than most states, giving claimants with 2023 or later diagnoses active filing windows. Michigan applies Daubert under MRE 702. Detroit-area claimants should consult national plaintiffs' counsel about Delaware Superior Court filing. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Resources for Detroit Zantac Claimants

Detroit-area Zantac claimants should gather pharmacy records from CVS, Walgreens, Meijer, and Rite Aid pharmacies, as well as UAW health fund pharmacy program records if applicable. Karmanos Cancer Institute and Henry Ford Cancer Institute records documenting bladder, esophageal, stomach, or colorectal cancer are critical evidence. Michigan's 3-year SOL provides additional time but immediate consultation with qualified Zantac counsel is still strongly recommended.